Tag
This analysis of BMT CTN 1202 reveals that rabbit ATG exposure influences survival, relapse, and immune recovery after T-replete hematopoietic cell transplantation, advocating for model-based dosing to optimize outcomes.
This study reveals early establishment of a diverse naïve B-cell receptor repertoire within 3 months post-pediatric HSCT, followed by gradual antigen-experienced maturation over 24 months, reflecting physiological B-cell development and sup
A Phase 2 study demonstrates that pharmacokinetic model-based ATG dosing significantly enhances CD4+ T-cell reconstitution in patients undergoing CD34+ selected hematopoietic cell transplantation, reaching primary endpoints in 70% of partic
